NUVECTIS PHARMA INC (NVCT) Stock News

NASDAQ:NVCT - Nasdaq - US67080T1088 - Common Stock - Currency: USD

7.78 +0.05 (+0.65%)

After market: 7.96 +0.18 (+2.31%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NVCT Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies

2 months ago - By: Benzinga - Mentions: RGC WORX PRTA STIM ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

2 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

2 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

3 months ago - By: Zacks Investment Research

Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?

3 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

3 months ago - By: Yahoo Finance - Mentions: DERM PFE DHI CMG ...

Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025

3 months ago - By: Yahoo Finance - Mentions: DERM CMRX MNPR MASS

Why Journey Medical Corporation (DERM) is Surging in 2025

3 months ago - By: Yahoo Finance - Mentions: VZ DERM DHI CMG

Americans saved money in fintechs. When money went missing, FDIC was no where to be found

3 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

3 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

4 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

4 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

4 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

4 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

5 months ago - By: Market News Alerts

Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

5 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

5 months ago - By: Market News Alerts

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

5 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

6 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

6 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

6 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

6 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

6 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

6 months ago - By: Benzinga - Mentions: CUTR ICAD PRPH ANVS ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

8 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

8 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

9 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

9 months ago - By: PESG Research

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

9 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics